◀ Back to NFKB1
LOX — NFKB1
Text-mined interactions from Literome
Bonizzi et al., Mol Cell Biol 1999
(Adenocarcinoma) :
Stimulation of lymphoid cells with interleukin-1beta (IL-1beta) led to ROI production and NF-kappaB activation, which could both be blocked by antioxidants or FLAP inhibitors, confirming that
5-LOX was the source of ROIs and was
required for
NF-kappaB activation in these cells ... However, reintroduction of a functional 5-LOX system in these cells allowed ROI production and
5-LOX dependent
NF-kappaB activation
Kandouz et al., Prostaglandins Other Lipid Mediat 2003
(Prostatic Neoplasms) :
The enzymatic product of arachidonic acid metabolism, 12 ( S ) -HETE, mediates the
activation of
NF-kappaB by the
12-LOX ... Considering the known involvement of MAP kinase pathway in NF-kappaB activation and that of 12 ( S ) -HETE in MAP kinase pathway,
12-LOX present in prostate cancer tissues may
contribute to the constitutive activation of
NF-kappaB in prostate cancer cells
Jatana et al., Journal of neuroinflammation 2006
:
BW-B 70C down-regulated
5-LOX and
inhibited iNOS expression by preventing
NF-kappaB activation
Bonizzi et al., J Immunol 1997
:
This study thus indicates that the activation of
NF-kappaB following IL-1beta treatment
involves the activation of phospholipase A2 and
5-LOX and the production of reactive oxygen intermediates ( ROIs ) in lymphoid cells, while in epithelial cells, another pathway predominates and could involve the acid sphingomyelinase